METHODS: A cohort of 556 mothers with preschoolers completed surveys to examine maternal mindful parenting, depression, parent-child relationships, and their children's emotional regulation ability. The inquiry attempted to understand the complex dynamics between the variables under consideration using moderated mediation analysis.
RESULTS: The findings revealed that higher levels of closeness in the parent-child relationship attenuated the link between maternal mindful parenting and maternal depressive symptoms. Conversely, parent-child relationships with less conflict intensified the connections between maternal mindful parenting and both maternal depression and the emotional regulation ability of preschoolers.
CONCLUSION: These findings enhance comprehension regarding the interconnectedness of maternal mindful parenting and preschoolers' emotional regulation ability within the Chinese cultural and familial milieu.
OBJECTIVE: This study aimed to investigate the effectiveness and safety of sulfonylurea therapy in Chinese NDM patients during infancy before genetic testing results were available.
METHODS: The medical records of NDM patients with their follow-up details were reviewed and molecular genetic analysis was performed. Sulfonylurea transfer regimens were applied in patients diagnosed after May 2010, and glycemic status and side effects were evaluated in each patient.
RESULTS: There were 23 NDM patients from 22 unrelated families, 10 had KCNJ11 mutations, 3 harbored ABCC8 mutations, 1 had INS mutations, 4 had chromosome 6q24 abnormalities, 1 had a deletion at chromosome 1p36.23p36.12, and 4 had no genetic abnormality identified. Sixteen NDM infants were treated with glyburide at an average age of 49 days (range 14-120 days) before genetic confirmation. A total of 11 of 16 (69%) were able to successfully switch to glyburide with a more stable glucose profile. The responsive glyburide dose was 0.51 ± 0.16 mg/kg/d (0.3-0.8 mg/kg/d), while the maintenance dose was 0.30 ± 0.07 mg/kg/d (0.2-0.4 mg/kg/d). No serious adverse events were reported.
CONCLUSIONS: Molecular genetic diagnosis is recommended in all patients with NDM. However, if genetic testing results are delayed, sulfonylurea therapy should be considered before such results are received, even in infants with newly diagnosed NDM.